GENE » Topics » Research and development expenses

This excerpt taken from the GENE 20-F filed Dec 20, 2007.

Research and development expenses

 

Research and development increased by $984,872 or approximately 53% to $2,815,804 in 2006 from $1,830,932 in 2005.  During the 2006 financial year, the Company continued to fund its five principal research and development projects and to incur additional expenditure in an effort to accelerate the commercialization of its RareCellect and ImmunAid projects, in particular.

 

This excerpt taken from the GENE 20-F filed Dec 28, 2006.

Research and development expenses

Research and development increased by $161,448 or approximately 10% to $1,830,932 in 2005 from $1,669,484 in 2004.  During the 2005 financial year, the Company continued to fund its five principal research and development projects and to incur additional expenditure in an effort to accelerate the commercialization of its RareCellect and ImmunAid projects, in particular.

This excerpt taken from the GENE 20-F filed Dec 30, 2005.

Research and development expenses

 

Research and development increased by $1,147,569 or approximately 224% to $1,659,914 in 2004 from $512,345 in 2003.  The research and development expenditure continued in relation to the Parasitology project, RareCellect project and the AIDS project in Melbourne, Australia.  The Company commenced new research projects with King’s College London and the C.Y. O’Connor ERADE Village Foundation in Western Australia.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki